The Dana-Farber Hodgkin's Lymphoma Combination Chemotherapy Trail

Gary Reis

The owner of the Pawtucket Country Club and the president of both Triton Fleet Services and Med Tech Ambulance Service, Gary Reis has spearheaded medical support operations in Pawtucket, Rhode Island, for more than two decades. He also supports multiple charitable organizations in the healthcare field and beyond. As a contributor to the Dana-Farber Cancer Institute, Gary Reis helps to fund a wide variety of research initiatives.

Among Dana-Farber’s research projects are hundreds of clinical trials that study new pharmaceuticals, diagnostic procedures, and other therapeutic treatments in order to assess their safety and effectiveness. These trials cover subjects that range from general stem cell transfer and gene therapy to specific conditions such as leukemia and histiocytosis.

Dana-Farber is currently recruiting participants for a phase 2 clinical trial that studies the effectiveness of combination chemotherapy, with or without radiation therapy, in the treatment of young patients with favorable-risk Hodgkin's lymphoma. The study postulates that prescribing combination chemotherapy in concert with radiation therapy may significantly increase the destruction of cancer cells in affected areas while allowing doctors to save adjacent body tissue. In order to complete this study, Dana-Farber has partnered with Massachusetts General Hospital and Boston Children's Hospital.